Ameriprise
ADMS

Ameriprise’s Adamas Pharmaceuticals ADMS Stock Holding History

Ameriprise’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,020
Closed -$32K – 3763
2020
Q1 		$32K Sell
11,020
-255,817
-96% -$1.15M ﹤0.01% 3596
2019
Q4 		$1.01M Sell
266,837
-752,158
-74% -$3.6M ﹤0.01% 3047
2019
Q3 		$5.21M Buy
1,018,995
+244,700
+32% +$1.51M ﹤0.01% 2189
2019
Q2 		$4.8M Buy
774,295
+623,705
+414% +$3.59M ﹤0.01% 2279
2019
Q1 		$1.07M Sell
150,590
-253
-0.2% -$2.27K ﹤0.01% 3007
2018
Q4 		$1.29M Buy
+150,843
New +$1.96M ﹤0.01% 2839
2018
Q1 		– Sell
-54,295
Closed -$1.84M – 3726
2017
Q4 		$1.84M Buy
+54,295
New +$1.52M ﹤0.01% 2690
2016
Q1 		– Sell
-64,978
Closed -$1.84M – 3910
2015
Q4 		$1.84M Buy
+64,978
New +$1.09M ﹤0.01% 2649

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Ameriprise's ADMS Position: Q2 2020 in Review

Ameriprise sold out of Adamas Pharmaceuticals (ADMS) in Q2 2020, closing a stake of 11,020 shares — an estimated $32K sold.

Ameriprise first reported a position in ADMS in Q4 2015 and held it in 8 quarters. The position peaked at $5.21M in Q3 2019. 61 funds tracked by Wall St. Rank hold ADMS as of Q2 2020.

  • Ameriprise reported no remaining Adamas Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Ameriprise sold 11,020 Adamas Pharmaceuticals shares in Q2 2020, an estimated $32K.
  • Ameriprise first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Ameriprise's Adamas Pharmaceuticals position peaked at $5.21M in Q3 2019.
  • 61 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2020.

Based on Ameriprise's 13F filing for Q2 2020, filed 14 Aug 2020.